Abstracts tagged "clinical trials and treatment"

Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].